A Novel Receptor Tyrosine Kinase Switch Promotes Gastrointestinal Stromal Tumor Drug Resistance

The fact that most gastrointestinal stromal tumors (GISTs) acquire resistance to imatinib (IM)-based targeted therapy remains the main driving force to identify novel molecular targets that are capable to increase GISTs sensitivity to the current therapeutic regimens. Secondary resistance to IM in G...

Descripción completa

Detalles Bibliográficos
Autores principales: Boichuk, Sergei, Galembikova, Aigul, Dunaev, Pavel, Valeeva, Elena, Shagimardanova, Elena, Gusev, Oleg, Khaiboullina, Svetlana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149963/
https://www.ncbi.nlm.nih.gov/pubmed/29206199
http://dx.doi.org/10.3390/molecules22122152

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6149963/
https://www.ncbi.nlm.nih.gov/pubmed/29206199
http://dx.doi.org/10.3390/molecules22122152

Ejemplares similares